Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004419 · ClinicalTrials.gov registry record · NA
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
A NA study of Insulin Resistance and Hyperglycemia, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00004419: Completed NA study of Insulin Resistance and Hyperglycemia, sponsored by Beth Israel Deaconess Medical Center.
NCT00004419 is a NA study of Insulin Resistance and Hyperglycemia that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 18 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004419, a NA study of Insulin Resistance and Hyperglycemia, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandrogenism, and hyperlipidemia in patients with severe insulin resistance who have failed other therapies. II. Determine the dose and time response of rhIGF-I on carbohydrate homeostasis and secondary abnormalities in this patient population. III. Determine the effect of rhIGF-I on insulin clearance, the regulation of insulin-like growth factor binding protein 1, the regulation of sex hormone binding globulin, and hypothalamic pituitary gonadal axis in this patient population.
Conditions Studied
Interventions
- DRUG insulin-like growth factor I
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1998-04 |
| Est. Completion | 2000-09 |
| Phase | NA |
What the finished NCT00004419 record still lists
NCT00004419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which insulin-like growth factor I is the first listed.
NCT00004419 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00004419 about?
NCT00004419 is a clinical study titled "Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance". OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandrogenism, and hyperlipidemia in patients with severe insulin resistance who have failed other therapies. II. Dete...
What is the current status of trial NCT00004419?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 1998-04. Estimated completion is 2000-09.
What conditions does trial NCT00004419 study?
This clinical trial studies the following conditions: Insulin Resistance, Hyperglycemia.
What interventions are being tested in trial NCT00004419?
The interventions under investigation include: insulin-like growth factor I (DRUG).
Who is sponsoring clinical trial NCT00004419?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004419 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004419's enrollment target sits among peer trials
18 105th of 120 higher than 16 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia